Rani Therapeutics Holdings, Inc. (RANI)
Largest Insider Buys in Sector
RANI Stock Price History Chart
RANI Stock Performance
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical …
Insider Activity of Rani Therapeutics Holdings, Inc.
Over the last 12 months, insiders at Rani Therapeutics Holdings, Inc. have bought $49,967 and sold $10.14M worth of Rani Therapeutics Holdings, Inc. stock.
On average, over the past 5 years, insiders at Rani Therapeutics Holdings, Inc. have bought $38.91M and sold $7.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: McKinley Kate (Chief Business Officer) — $29,993. Imran Talat (Chief Executive Officer) — $19,974.
The last purchase of 17,960 shares for transaction amount of $29,993 was made by McKinley Kate (Chief Business Officer) on 2024‑12‑13.
List of Insider Buy and Sell Transactions, Rani Therapeutics Holdings, Inc.
| 2024-12-13 | Chief Business Officer | 17,960 0.0313% | $1.67 | $29,993 | -13.25% | |||
| 2024-12-09 | Chief Executive Officer | 10,296 0.018% | $1.94 | $19,974 | -15.80% | |||
| 2024-10-15 | Sale | 10 percent owner | 3.83M 8.9999% | $2.65 | $10.14M | -3.30% | ||
| 2023-12-06 | Chief Executive Officer | 10,000 0.0173% | $2.27 | $22,700 | +29.18% | |||
| 2023-12-04 | Chief Executive Officer | 5,000 0.0101% | $2.57 | $12,850 | +34.14% | |||
| 2023-11-29 | Chief Executive Officer | 20,000 0.0409% | $2.05 | $41,000 | +70.26% | |||
| 2023-11-24 | Sale | 10 percent owner | 5.27M 10.2552% | $2.01 | $10.58M | +65.42% | ||
| 2023-11-24 | 10 percent owner | 5.27M 10.2552% | $2.01 | $10.58M | +65.42% | |||
| 2023-11-17 | director | 50,500 0.0962% | $2.03 | $102,495 | +65.17% | |||
| 2023-11-16 | director | 500 0.0009% | $1.98 | $990 | +65.75% | |||
| 2023-11-07 | Chief Executive Officer | 5,000 0.0095% | $2.00 | $9,975 | +67.17% | |||
| 2023-05-12 | 10 percent owner | 2,645 0.0104% | $3.98 | $10,529 | -10.45% | |||
| 2023-05-11 | 10 percent owner | 2,610 0.0102% | $3.87 | $10,096 | -8.04% | |||
| 2023-05-08 | 10 percent owner | 4,420 0.0183% | $4.46 | $19,733 | -15.65% | |||
| 2023-05-03 | 10 percent owner | 2,040 0.0082% | $4.81 | $9,816 | -23.68% | |||
| 2023-04-28 | 10 percent owner | 2,173 0.0086% | $4.71 | $10,225 | -23.40% | |||
| 2023-04-25 | 10 percent owner | 4,423 0.0172% | $4.51 | $19,952 | -21.35% | |||
| 2023-04-24 | 10 percent owner | 4,280 0.0169% | $4.67 | $19,994 | -23.19% | |||
| 2023-04-21 | 10 percent owner | 4,100 0.0166% | $4.93 | $20,224 | -25.47% | |||
| 2023-04-20 | 10 percent owner | 1,850 0.0074% | $5.32 | $9,851 | -31.72% |
Insider Historical Profitability
| South Cone Investments Limited Partnership | 10 percent owner | 8302194 14.4568% | $1.38 | 64 | 1 | <0.0001% |
| Imran Talat | Chief Executive Officer | 494751 0.8615% | $1.38 | 5 | 0 | |
| McKinley Kate | Chief Business Officer | 17960 0.0313% | $1.38 | 1 | 0 | |
| Quiroga Moreno Isidoro | 10 percent owner | 11731654 20.4286% | $1.38 | 2 | 0 | +50.37% |
| BUTEL JEAN LUC | director | 50500 0.0879% | $1.38 | 1 | 0 |
Institutional Investor Ownership
| The Vanguard Group | $2.13M | 1.36 | 685,303 | +2.54% | +$52,733.15 | <0.0001 | |
| Nan Fung Group | $1.54M | 0.98 | 493,584 | 0% | +$0 | 1.67 | |
| USAA | $1.5M | 0.96 | 481,300 | 0% | +$0 | 0.04 | |
| Alphabet | $1.39M | 0.89 | 448,492 | 0% | +$0 | 0.01 | |
| Stifel | $411,866.00 | 0.26 | 132,434 | +163.47% | +$255,540.16 | <0.0001 |